Grant: Discovery Grants Program - Individual
Université de Sherbrooke
$34,372.00
Immune responses to staphylococcus aureus
FY 2011-12
Summary
Staphylococcus aureus is a common bacteria which, in its antibiotic resistant form (MRSA), has become a common and dangerous hospital infection. It also causes mastitis in dairy cattle which is responsible for serious losses to the dairy industry. Unfortunately, most vaccines described up until now are only partially protective and are specific to certain types of infection. This research program which has been underway for several years was designed to study how S. aureus causes changes in the protective responses (immune responses) of infected animals and how these responses alter the efficiency of vaccines. A combination of vaccines made from genetic material (DNA) and proteins of the bacterium has been injected into mice which were then infected with the bacteria. Such DNA/protein vaccines are a relatively new technology that has recently been licensed for some fish viruses and West Nile virus in horses. Our results have suggested that each manifestation of S. aureus infection, be it arthritis, septicemia, endocarditis or mastitis, stimulates a slightly different immune response by the animal. Vaccination against the infection in one part of the body does not necessarily protect against infections at other sites. Thus it is important to identify how the immune responses differ from infection to infection. The immediate objective of this program is to study how the immune responses to S. aureus in mouse models vary during infections at different sites. The longer-term objectives of this program will be to find out how the immune response changes after the animals have been injected with different prototype vaccines. We will continue to use mouse models of S. aureus-induced septicemia, arthritis and mastitis, but we will also use a simulation of the bacterial colonization of the nose. This is often where the bacteria appears to be present in humans but without causing any symptoms. This ""nasal carriage"" may explain how antibiotic resistant bacteria have spread so fast. The success of such a project will have an important impact in the fight against other emerging and potentially dangerous bacteria.
Program
Discovery Grants Program - Individual
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
3525-2008
Name nom
Talbot, Brian
Department département
Biologie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2008
Award amount
34372
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
32
Committee name en
Cell Biology
Committee name fr
Biologie cellulaire
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5204
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Immunology
Research subject fr
Immunologie
Partie
4
Nb partie
5
Application title
Immune responses to staphylococcus aureus
Keyword
NSERC
Application summary
Staphylococcus aureus is a common bacteria which, in its antibiotic resistant form (MRSA), has become a common and dangerous hospital infection. It also causes mastitis in dairy cattle which is responsible for serious losses to the dairy industry. Unfortunately, most vaccines described up until now are only partially protective and are specific to certain types of infection. This research program which has been underway for several years was designed to study how S. aureus causes changes in the protective responses (immune responses) of infected animals and how these responses alter the efficiency of vaccines. A combination of vaccines made from genetic material (DNA) and proteins of the bacterium has been injected into mice which were then infected with the bacteria. Such DNA/protein vaccines are a relatively new technology that has recently been licensed for some fish viruses and West Nile virus in horses. Our results have suggested that each manifestation of S. aureus infection, be it arthritis, septicemia, endocarditis or mastitis, stimulates a slightly different immune response by the animal. Vaccination against the infection in one part of the body does not necessarily protect against infections at other sites. Thus it is important to identify how the immune responses differ from infection to infection. The immediate objective of this program is to study how the immune responses to S. aureus in mouse models vary during infections at different sites. The longer-term objectives of this program will be to find out how the immune response changes after the animals have been injected with different prototype vaccines. We will continue to use mouse models of S. aureus-induced septicemia, arthritis and mastitis, but we will also use a simulation of the bacterial colonization of the nose. This is often where the bacteria appears to be present in humans but without causing any symptoms. This ""nasal carriage"" may explain how antibiotic resistant bacteria have spread so fast. The success of such a project will have an important impact in the fight against other emerging and potentially dangerous bacteria.